Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O00483
UPID:
NDUA4_HUMAN
Alternative names:
Complex I-MLRQ; NADH-ubiquinone oxidoreductase MLRQ subunit
Alternative UPACC:
O00483; A4D109; Q6FHN5
Background:
Cytochrome c oxidase subunit NDUFA4, also known as Complex I-MLRQ and NADH-ubiquinone oxidoreductase MLRQ subunit, plays a pivotal role in the mitochondrial electron transport chain. It is a crucial component of cytochrome c oxidase, the enzyme responsible for the reduction of oxygen to water, facilitating oxidative phosphorylation and ATP synthesis. This process is vital for cellular energy production.
Therapeutic significance:
The protein is linked to Mitochondrial complex IV deficiency, nuclear type 21, a disorder marked by congenital lactic acidosis, encephalopathy, and motor dysfunction. Understanding the role of Cytochrome c oxidase subunit NDUFA4 could open doors to potential therapeutic strategies for this mitochondrial disorder.